// App-Quantinova.ai

AB0446 (2017) : ADDITIVE INHIBITION OF INTERFERONS, B AND T CELL ACTIVATION AND TFH-RELATED CYTOKINE CXCL13 BY LEFLUNOMIDE AND HYDROXYCHLOROQUINE SUPPORTS RATIONALE FOR COMBINATION THERAPY IN PSS PATIENTS

Researchers

Presenter

  • E.H. van der Heijden

Principal Investigators

  • S.A. Hartgring

  • A.A. Kruize

  • T.R. Radstake

  • J.A. van Roon

Medical Centers

  • Laboratory of Translational Immunology

  • Rheumatology and Clinical Immunology, ARC Amsterdam; UMC Utrecht, Utrecht, Netherlands

Locations

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Peripheral blood mononuclear cell

  • C-X-C Motif Chemokine Ligand 13

  • Immunoglobulin G

  • Interferon-alpha

  • Interferon-gamma

Drug/Treatment

  • Hydroxychloroquine

  • HWA-486

  • Interferon Gamma

  • IFN-lambda

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved